SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model

SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model

Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2D) share common features, including insulin resistance. Brain insulin resistance has been implicated as a key factor in the pathogenesis of AD. Recent studies have demonstrated that anti-diabetic drugs sodium–glucose cotransporter-2 inhibitor...

Full description

Bibliographic Details
Main Authors: A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Alzheimer’s disease
Type 2 diabetes mellitus
Sodium–glucose cotransporter-2 inhibitor
Dipeptidyl peptidase-4 inhibitor
Hyperphosphorylated tau
Amyloid β
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223015536

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223015536

Similar Items